Showing 4661-4670 of 5646 results for "".
- CEO says Pfizer “Very Close” to Filing COVID-19 Vaccine for US Emergency Usehttps://modernod.com/news/ceo-says-pfizer-very-close-to-filing-covid-19-vaccine-for-us-emergency-use/2478573/Pfizer CEO Albert Bourla suggested Tuesday that an FDA emergency-use authorization (EUA) request for the coronavirus vaccine it is co-developing with BioNTech is imminent. “We are very close to submitting for an [EUA],” Bourla reportedly said at a STAT News summit, but he would not sp
- Amazon Unveils Pharmacy Offering, Hitting Shares of Drug Retailershttps://modernod.com/news/amazon-unveils-pharmacy-offering-hitting-shares-of-drug-retailers/2478569/Amazon.com announced Tuesday the launch of Amazon Pharmacy, allowing customers in the US to complete an entire pharmacy transaction on their desktop or mobile device through the Amazon app. The move sent shares in other drug retailers down, with Walgreens Boots falling over 11%, CVS Health slippi
- Topcon Announces Launch of Chronos Binocular Refraction Systemhttps://modernod.com/news/topcon-announces-the-us-launch-of-chronos/2478562/Topcon Healthcare announced that it has launched the Chronos Automated Binocular Refraction System with SightPilot guided refraction software. Topcon Chronos is a digital refraction solution that combines autorefraction, keratometry, and subjective refraction in a single device that occupi
- Innovent Announces the Results of the Phase 1 Clinical Trial of IBI302 for Wet AMD at AAO 2020https://modernod.com/news/innovent-announces-the-results-of-the-phase-1-clinical-trial-of-ibi302-for-wet-amd-at-aao-2020/2478560/Innovent Biologics announces that the results of the phase 1 clinical trial of IBI302, a first-in-class ophthalmic recombinant human anti-VEGF and anti-complement bi-specific fusion protein for wet age-related macular degeneration (AMD) is released in e-poster at 2020 American Academy of Ophthalm
- Kodiak Sciences Completes Enrollment of Phase 2b/3 Pivotal Study of KSI-301 in Patients with Wet AMDhttps://modernod.com/news/kodiak-sciences-completes-enrollment-of-phase-2b-3-pivotal-study-of-ksi-301-in-patients-with-wet-amd/2478561/Kodiak Sciences announced that recruitment has concluded in its DAZZLE pivotal study of KSI-301, Kodiak’s anti-VEGF antibody biopolymer conjugate, in patients with wet age-related macular degeneration (AMD). DAZZLE was planned to enroll 550 treatment-naïve patients worldwide; the target enr
- Adverum Biotechnologies Announces Positive Interim Data From OPTIC Phase 1 Trial of ADVM-022 Intravitreal Gene Therapy for Wet AMDhttps://modernod.com/news/adverum-biotechnologies-announces-positive-interim-data-from-optic-phase-1-trial-of-advm-022-intravitreal-gene-therapy-for-wet-amd/2478553/Adverum Biotechnologies announced positive new interim data from Cohorts 1-4 of the OPTIC phase 1 clinical trial of ADVM-022 intravitreal (IVT) injection gene therapy in patients requiring frequent anti-VEGF injections for their wet age-related macular degeneration (AMD). “With these impre
- Rural Hospitals Struggle to Find Places to Transfer Patients Amid COVID-19 Surgeshttps://modernod.com/news/rural-hospitals-struggle-to-find-places-to-transfer-patients-amid-covid-19-surges/2478551/Norton County Hospital is facing a major problem in recent days: Figuring out where to send patients that need a higher level of care. As larger hospitals become overwhelmed with serious cases of COVID-19, the options are dwindling. For Norton, the closest hospital that it has been able to
- Oyster Point Pharma Announces Clinical Data Presentations on OC-01 Nasal Spray for Dry Eye Disease at AAO Virtualhttps://modernod.com/news/oyster-point-pharma-announces-clinical-data-presentations-on-oc-01-nasal-spray-for-dry-eye-disease-at-aao-virtual/2478548/Oyster Point Pharma announced new data from its phase 2 IMPERIAL clinical trial evaluating OC-01 (varenicline) nasal spray in the treatment of the signs and symptoms of dry eye disease in adults at the AAO 2020 Virtual Annual Meeting, being held on November 13-15. A single administration o
- Apellis Announces Late-Breaking Presentation of Largest Retrospective Database Study in Geographic Atrophy at AAO 2020 Virtualhttps://modernod.com/news/apellis-announces-late-breaking-presentation-of-largest-retrospective-database-study-in-geographic-atrophy-at-aao-2020-virtual/2478547/Apellis Pharmaceuticals announced findings from a large retrospective database study in geographic atrophy (GA) secondary to age-related macular degeneration (AMD). The analysis of the American Academy of Ophthalmology IRIS (Intelligent Research in Sight) Registry was conducted in partnership wit
- Gemini Therapeutics Announces GEM103 Meets All Endpoints in Phase 1 Clinical Studyhttps://modernod.com/news/gemini-therapeutics-announces-gem103-meets-all-endpoints-in-phase-1-clinical-study/2478546/Gemini Therapeutics announced that the phase 1 study of GEM103, the company’s investigational treatment for dry AMD, met all its endpoints. Results demonstrate that in 12 patients receiving a single intravitreal (IVT) injection of GEM103, there were no dose-limiting toxicities or treatment-